Suppr超能文献

骨形态发生蛋白-9控制肺血管生长和重塑。

Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling.

作者信息

Berrebeh Nihel, Mbouamboua Yvon, Thuillet Raphaël, Ottaviani Mina, Robert Fabien, Kamel Chelgham Mustapha, Magnone Virginie, Desroches-Castan Agnès, Ricard Nicolas, Anegon Ignacio, Remy Séverine, Schermuly Ralph Theo, Lebrigand Kevin, Kojonazarov Baktybek, Savale Laurent, Humbert Marc, Bailly Sabine, Barbry Pascal, Tu Ly, Guignabert Christophe

机构信息

INSERM, UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies (HPPIT), Le Kremlin-Bicêtre 94276, France.

Université Paris-Saclay, Faculté de Médecine, HPPIT, Le Kremlin-Bicêtre 94276, France.

出版信息

Proc Natl Acad Sci U S A. 2025 Jul;122(26):e2410229122. doi: 10.1073/pnas.2410229122. Epub 2025 Jun 23.

Abstract

Pulmonary arterial hypertension (PAH) and hereditary hemorrhagic telangiectasia (HHT) are two distinct vascular diseases linked to impaired signaling through bone morphogenetic protein (BMP) receptor complexes in endothelial cells. Although BMP-9 plays a central role in activating this pathway by binding to ALK1 and BMPR-II, its precise function in the pulmonary microvasculature has remained unclear. In this study, we demonstrate a role for BMP-9 in regulating pulmonary vascular architecture and homeostasis. Our findings reveal that BMP-9 signaling intersects with VEGF pathways and contributes to the delicate balance between vascular growth and remodeling in the lungs. We also show that disruption of this pathway can shift vascular responses toward an HHT-like state, potentially altering disease susceptibility. These insights offer a unique perspective on how BMP-9 and ALK1 shape pulmonary vascular biology and suggest that targeting this axis could inform future strategies for treating complex vascular diseases such as PAH.

摘要

肺动脉高压(PAH)和遗传性出血性毛细血管扩张症(HHT)是两种不同的血管疾病,它们与内皮细胞中骨形态发生蛋白(BMP)受体复合物信号传导受损有关。尽管BMP-9通过与ALK1和BMPR-II结合在激活该信号通路中起核心作用,但其在肺微血管中的精确功能仍不清楚。在本研究中,我们证明了BMP-9在调节肺血管结构和稳态中的作用。我们的研究结果表明,BMP-9信号与VEGF信号通路相互作用,并有助于肺血管生长和重塑之间的微妙平衡。我们还表明,该信号通路的破坏可使血管反应向类似HHT的状态转变,可能改变疾病易感性。这些见解为BMP-9和ALK1如何塑造肺血管生物学提供了独特的视角,并表明靶向该轴可能为治疗PAH等复杂血管疾病的未来策略提供依据。

相似文献

1
Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling.
Proc Natl Acad Sci U S A. 2025 Jul;122(26):e2410229122. doi: 10.1073/pnas.2410229122. Epub 2025 Jun 23.
5
BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension.
Circulation. 2024 Jul 9;150(2):132-150. doi: 10.1161/CIRCULATIONAHA.123.066430. Epub 2024 Apr 1.
6
A systematic review of genetic mutations in pulmonary arterial hypertension.
BMC Med Genet. 2017 Aug 2;18(1):82. doi: 10.1186/s12881-017-0440-5.
7
[Dysfunction of endothelial BMP-9 signaling in pulmonary vascular disease].
Rev Mal Respir. 2023 Mar;40(3):234-238. doi: 10.1016/j.rmr.2023.01.017. Epub 2023 Feb 23.
8
MHCIILYVE1CCR2 Interstitial Macrophages Promote Medial Fibrosis in Pulmonary Arterioles and Contribute to Pulmonary Hypertension.
Circ Res. 2025 Jun 20;137(1):46-66. doi: 10.1161/CIRCRESAHA.125.326173. Epub 2025 May 13.
9
ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation.
Arterioscler Thromb Vasc Biol. 2018 May;38(5):1216-1229. doi: 10.1161/ATVBAHA.118.310760. Epub 2018 Feb 15.

引用本文的文献

1
In vitro and in vivo characterization of wild type BMP9 and a non-osteogenic variant in models of pulmonary arterial hypertension.
PLoS One. 2025 Jul 28;20(7):e0329089. doi: 10.1371/journal.pone.0329089. eCollection 2025.

本文引用的文献

1
Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension.
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01483-2024. Print 2024 Oct.
2
Pathology and pathobiology of pulmonary hypertension: current insights and future directions.
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01095-2024. Print 2024 Oct.
3
Genetic or therapeutic neutralization of ALK1 reduces LDL transcytosis and atherosclerosis in mice.
Nat Cardiovasc Res. 2023 May;2(5):438-448. doi: 10.1038/s44161-023-00266-2. Epub 2023 May 11.
4
Disrupted BMP-9 Signaling Impairs Pulmonary Vascular Integrity in Hepatopulmonary Syndrome.
Am J Respir Crit Care Med. 2024 Sep 1;210(5):648-661. doi: 10.1164/rccm.202307-1289OC.
5
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6.
6
BMP10 functions independently from BMP9 for the development of a proper arteriovenous network.
Angiogenesis. 2023 Feb;26(1):167-186. doi: 10.1007/s10456-022-09859-0. Epub 2022 Nov 8.
7
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.01347-2022. Print 2023 Jan.
8
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.00879-2022. Print 2023 Jan.
9
Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats.
Hypertension. 2022 Oct;79(10):2262-2273. doi: 10.1161/HYPERTENSIONAHA.122.19207. Epub 2022 Aug 18.
10
New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis.
Circ Res. 2022 Apr 29;130(9):1365-1381. doi: 10.1161/CIRCRESAHA.122.320084. Epub 2022 Apr 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验